Appl. No. 09/652,493 Amdt. Dated December 17, 2004 Reply to Office action of May 18, 2004

- c. <u>providing a normal value for α-dystroglycan expression levels on cell</u> <u>surfaces; and</u>
- d. comparing the detection levels of α-dystroglycan to said normal value, whereby the absence a decrease in levels of α-dystroglycan on said cells of the sample indicates a higher potential for tumorigenicity.

Claim 6 (Currently amended): The method of claim 5, wherein said detecting comprises:

- a. adding to said sample a monoclonal antibody specific for to α-dystroglycan, and
- b. measuring the amount of labeled a-dystroglycan detected.

Claim 7 (Original): The method of claim 5, wherein said cells are human mammary epithelial cells.

Claim 8 (Currently amended): The method of claim 5, wherein the step of providing a normal value comprises measuring said detecting comprises measurement of the amount of a dystroglycan relative to the amount of β -dystroglycan on the surface of said cells, wherein a relative decrease in the ratio of α -dystroglycan to β -dystroglycan indicates α -dystroglycan shedding and higher potential tumorigenicity.

Claims 9 - 21 (Canceled).

Claim 22 (Currently amended): A method of determining the likelihood that a patient has a tumor, by assaying proteolysed a-dystroglycan fragments shed from a cell into blood in patient serum, said method comprising the steps of:

Appl. No. 09/652,493 Amdt. Dated December 17, 2004 Reply to Office action of May 18, 2004

- a. contacting a serum sample to be assayed with a labeled antibody specific for an-α-dystroglycan fragment, and
- b. assaying the amount of bound label,

whereby wherein said a-dystroglycan fragments bound to said labeled antibody are is positively correlated with existence of a tumor cell growth in the patient.

Claim 23 (Currently amended): The method of Claim 22, wherein the α-dystroglycan fragment is an a fragment of approximately 120 kD fragment.

Claim 24 (Currently amended): The method of Claim 22, wherein the α-dystroglycan fragment is an a fragment of approximately 60 kD fragment.

Claims 25 - 28 (Canceled).

Claim 29 (Currently amended): The method of claim 22, wherein said <u>tumor</u> cell is an epithelial cell <u>tumor</u>.

Claim 30 (Currently amended): The method of claim 29, wherein said epithelial cell tumor is a breast epithelial cell tumor.